Head and neck oncology research evaluates organ-preserving therapies, immunotherapy combinations, and HPV-stratified treatment paradigms.
In the open-label phase 2 CAMORAL trial (125 patients with resectable stage III to IVB head and neck squamous cell carcinoma), perioperative camrelizumab plus chemotherapy raised 2-year event-free survival to 77.8% (95% CI, 63.6-87.0) versus 46.1% (95% CI, 31.3-59.6) with upfront surgery (stratified HR, 0.34; 95% CI, 0.17-0.68; P = .001).
PEMDA-HN was a multicenter, randomized, open-label phase 2 study at 22 centers in 3 countries comparing danvatirsen plus pembrolizumab with pembrolizumab alone as first-line treatment in PD-L1-positive (combined positive score ≥1) recurrent or metastatic head and neck squamous cell carcinoma. Of 69 patients randomized 2:1, 66 were treated (45 vs 21). The confirmed objective response rate, the primary endpoint, was 15.6% (7/45) with the combination vs 14.3% (3/21) with pembrolizumab alone (risk difference 1.3; 90% CI −14.1 to 16.7; Fisher's exact P = 1.0000).
VERSATILE-002 was a phase 2, open-label, multicenter, nonrandomized trial of the HPV16 E6/E7 peptide vaccine PDS0101 combined with pembrolizumab in HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma. 87 patients were treated in two separately analyzed cohorts: immune checkpoint inhibitor (ICI)-naive and ICI-resistant.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.